NCT02924038: A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) |
|
|
| Terminated | 1 | 14 | US | IMA950, IMA950 peptides, poly-ICLC, Hiltonol, Varlilumab, CDX-1127 | Nicholas Butowski, Celldex Therapeutics, National Cancer Institute (NCI) | Glioma, Malignant Glioma, Astrocytoma, Grade II, Oligodendroglioma, Glioma, Astrocytic, Oligoastrocytoma, Mixed | 12/22 | 12/22 | | |
